Is retatrutide the best new drug for weight loss and type 2 diabetes?

Retatrutide is a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Early trials show it delivers greater weight loss than semaglutide and tirzepatide, while also improving blood sugar, liver fat, and cholesterol. FDA approval may come as early as 2027.

Instalab Research

Retatrutide is being called the most powerful weight loss drug we’ve seen to date, and for good reason. In clinical trials, people with obesity lost up to 24% of their body weight in just 48 weeks. That’s even more than what we’ve seen with semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound). It’s not just about the scale either. Retatrutide also improves blood sugar, liver health, and cholesterol, all without causing low blood sugar or serious side effects in most patients.

Let’s break down how this triple-action drug works and what you should know before it hits the market.

What Makes Retatrutide Different?

Retatrutide is part of a new class of drugs called triple hormone receptor agonists. That means it activates three different metabolic hormone receptors in your body:

GLP-1 receptor: Helps reduce appetite, lower blood sugar, and delay stomach emptying.
GIP receptor: Enhances insulin release and improves fat metabolism.
Glucagon receptor: Increases energy expenditure by helping your body burn fat and sugar.

This multi-target approach seems to amplify the benefits seen with older GLP-1 drugs. By hitting all three receptors, retatrutide doesn’t just suppress appetite, it ramps up how much energy your body burns, improving fat loss and metabolic health at the same time.

The Results So Far Are Impressive

Weight loss: Up to 24.2% body weight reduction in 48 weeks at the highest dose (12 mg weekly).
Blood sugar: HbA1c (a 3-month average of blood glucose) dropped by up to 2.2% in people with type 2 diabetes.
Liver fat: In patients with MASLD (metabolic dysfunction-associated steatotic liver disease), liver fat decreased by over 80%.
Cholesterol and triglycerides: Levels of LDL, VLDL, and other atherogenic lipids dropped significantly.

These effects are dose-dependent, meaning higher doses produce greater benefits, though side effects also tend to increase slightly with dose.

How Does It Compare to Other GLP-1 Drugs?

Drug (Max Dose)	Weight Loss	HbA1c Reduction
Retatrutide (12 mg)	24.2%	Up to -2.2%
Tirzepatide (15 mg)	~20%	Up to -2.0%
Semaglutide (2.4 mg)	12–15%	Up to -1.8%

Retatrutide leads the pack for weight loss and rivals the best-in-class for glycemic control. It’s not yet FDA-approved, but early results suggest it may become the top choice for patients with obesity and type 2 diabetes once it’s available.

What About Side Effects?

Most side effects are mild to moderate and similar to what we’ve seen with GLP-1 drugs:

Nausea
Vomiting
Diarrhea
Constipation

These tend to happen early on and improve with time. Starting at a lower dose and gradually increasing can help reduce symptoms. More serious risks like pancreatitis or gallbladder issues haven’t shown up in the data so far, but longer-term safety studies are still underway.

Other Health Benefits

Early research shows retatrutide may also:

Improve insulin sensitivity (how well your body uses insulin)
Restore beta-cell function (the cells that make insulin)
Reduce blood pressure
Improve kidney markers
Possibly help fight triple-negative breast cancer by disrupting how cancer cells metabolize fuel (early-stage data)

When Will Retatrutide Be Available?

Retatrutide is currently in Phase 3 trials. If all goes well, Eli Lilly plans to submit it to the FDA in 2026, with potential approval by 2027. Like semaglutide and tirzepatide, it will likely be available as a once-weekly injection. If approved, it could use the same injector pens that many patients are already familiar with from Lilly’s other drugs.

Final Thoughts

If you’re dealing with obesity, type 2 diabetes, or metabolic liver disease, retatrutide could represent the next leap forward in treatment. It’s showing the highest weight loss seen in any clinical trial so far, plus a wide range of metabolic benefits that go beyond the scale.

We’ll still need head-to-head comparisons and long-term safety data, especially in people with heart disease or kidney problems. But for now, retatrutide looks like a serious contender to become the most effective metabolic drug on the market.

References

J. Tewari et al. "Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis." Expert Review of Clinical Pharmacology, 18 (2025): 51 - 66. https://doi.org/10.1080/17512433.2025.2450254.
J. Rosenstock et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The Lancet, 402 (2023): 529-544. https://doi.org/10.1016/S0140-6736(23)01053-X.
Ania M. Jastreboff et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial." The New England journal of medicine (2023). https://doi.org/10.1056/NEJMoa2301972.
Toufik Abdul-Rahman et al. "The power of three: Retatrutide's role in modern obesity and diabetes therapy." European journal of pharmacology, 985 (2024): 177095. https://doi.org/10.1016/j.ejphar.2024.177095.
Arun J Sanyal et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial." Nature Medicine, 30 (2024): 2037 - 2048. https://doi.org/10.1038/s41591-024-03018-2.
S. Doggrell et al. "Retatrutide showing promise in obesity (and type 2 diabetes)." Expert Opinion on Investigational Drugs, 32 (2023): 997 - 1001. https://doi.org/10.1080/13543784.2023.2283020.
Xin Cui et al. "Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP." Advanced Science, 12 (2025). https://doi.org/10.1002/advs.202407494.
Avik Ray et al. "Retatrutide: a triple incretin receptor agonist for obesity management." Expert Opinion on Investigational Drugs, 32 (2023): 1003 - 1008. https://doi.org/10.1080/13543784.2023.2276754.
S. Urva et al. "The novel GIP, GLP‐1 and glucagon receptor agonist retatrutide delays gastric emptying." Diabetes, 25 (2023): 2784 - 2788. https://doi.org/10.1111/dom.15167.
Julio Rosenstock et al. "266-OR: Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta-Cell Function and Insulin Sensitivity." Diabetes (2024). https://doi.org/10.2337/db24-266-or.
Valentina Pirro et al. "117-OR: Effects of Triple-Hormone Receptor Agonist Retatrutide on Lipid Profiling in Participants with Obesity." Diabetes (2024). https://doi.org/10.2337/db24-117-or.
S. Nicholls et al. "Triple-hormone receptor agonist retatrutide significantly improves lipoprotein and apolipoprotein profiles in participants with obesity or overweight." European Heart Journal (2024). https://doi.org/10.1093/eurheartj/ehae666.1501.
H. Heerspink et al. "754-P: Effect of Retatrutide on Kidney Parameters in People with Type 2 Diabetes and/or Obesity—A Post-Hoc Analysis of Two Phase 2 Trials." Diabetes (2024). https://doi.org/10.2337/db24-754-p.
Zeyu Xie et al. "Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.." Metabolism: clinical and experimental (2024): 156038. https://doi.org/10.1016/j.metabol.2024.156038.
Y. Wen et al. "Reduction of triglyceride-rich lipoproteins with retatrutide in type 2 diabetes may be explained by concurrent reduction in ANGPTL3/8 levels." European Heart Journal (2024). https://doi.org/10.1093/eurheartj/ehae666.2862.
T. Salmen et al. "Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review." Pharmaceuticals, 17 (2024). https://doi.org/10.3390/ph17101322.